Madrigal Pharmaceuticals Inc Asset Resilience Ratio
Madrigal Pharmaceuticals Inc asset resilience ratio. Madrigal Pharmaceuticals Inc (MDGL) has an Asset Resilience Ratio of 62.31% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Madrigal Pharmaceuticals Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Madrigal Pharmaceuticals Inc (2003–2025)
Asset resilience ratio of Madrigal Pharmaceuticals Inc from 2003 to 2025. This chart shows how Madrigal Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See MDGL free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Madrigal Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see MDGL asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $784.87 Million | 62.31% |
| Total Liquid Assets | $784.87 Million | 62.31% |
Asset Resilience Insights
- Very High Liquidity: Madrigal Pharmaceuticals Inc maintains exceptional liquid asset reserves at 62.31% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Madrigal Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Madrigal Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Madrigal Pharmaceuticals Inc Asset Resilience Ratio by Year (2003–2025)
Madrigal Pharmaceuticals Inc asset resilience ratio by year from 2003 to 2025. The table below shows the annual Asset Resilience Ratio data for Madrigal Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 62.31% | $784.87 Million | $1.26 Billion | -16.96pp |
| 2024-12-31 | 79.27% | $826.23 Million | $1.04 Billion | -4.13pp |
| 2023-12-31 | 83.40% | $534.22 Million | $640.55 Million | +75.89pp |
| 2022-12-31 | 7.51% | $27.23 Million | $362.57 Million | -78.13pp |
| 2021-12-31 | 85.64% | $234.08 Million | $273.33 Million | +5.45pp |
| 2020-12-31 | 80.19% | $230.15 Million | $287.00 Million | -8.56pp |
| 2019-12-31 | 88.76% | $392.35 Million | $442.06 Million | +0.93pp |
| 2018-12-31 | 87.83% | $426.34 Million | $485.43 Million | +65.52pp |
| 2017-12-31 | 22.31% | $42.90 Million | $192.31 Million | -29.51pp |
| 2016-12-31 | 51.82% | $21.35 Million | $41.21 Million | +5.47pp |
| 2015-12-31 | 46.35% | $31.61 Million | $68.19 Million | -4.97pp |
| 2014-12-31 | 51.32% | $51.67 Million | $100.67 Million | +6.17pp |
| 2013-12-31 | 45.15% | $42.99 Million | $95.20 Million | +26.62pp |
| 2012-12-31 | 18.53% | $19.09 Million | $103.02 Million | -4.27pp |
| 2011-12-31 | 22.80% | $9.65 Million | $42.32 Million | -13.57pp |
| 2010-12-31 | 36.37% | $19.66 Million | $54.07 Million | +14.24pp |
| 2008-12-31 | 22.13% | $21.52 Million | $97.25 Million | -1.85pp |
| 2006-12-31 | 23.98% | $13.14 Million | $54.79 Million | -29.73pp |
| 2005-12-31 | 53.71% | $38.25 Million | $71.21 Million | -8.58pp |
| 2004-12-31 | 62.29% | $82.23 Million | $132.02 Million | +12.32pp |
| 2003-12-31 | 49.96% | $40.16 Million | $80.39 Million | -- |
About Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.